Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2022

02-09-2022 | Rituximab | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Pemphigus for the Inpatient Dermatologist

Authors: Connor Cole, Kyle Amber

Published in: Current Dermatology Reports | Issue 4/2022

Login to get access

Abstract

Purpose of Review

Although detailed guidelines exist for the general treatment of pemphigus, reviews specific to inpatient management are sparse. This paper will seek to provide a comprehensive and centralized guide for the treatment of this disease by the inpatient dermatologist.

Recent Findings

Important recent findings include the demonstrated efficacy of rituximab as a first-line agent in pemphigus and its approval by the FDA for the treatment of moderate-to-severe pemphigus in adults in 2018.

Summary

Optimal care for pemphigus in the hospital requires a multi-disciplinary approach, which factors in specific qualities of each patient to develop the proper medication regimen and treatment plan. In addition, proper wound and oral care, diet, and prophylaxis against potential complications are all crucial to timely and appropriate discharge.
Literature
1.
Di Zenzo G, et al. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol. 2016;38(1):57–74.CrossRef
2.
Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018;9:1190.CrossRef
3.
Hassona Y, et al. Diagnostic patterns and delays in autoimmune blistering diseases of the mouth: a cross-sectional study. Oral Dis. 2018;24(5):802–8.CrossRef
4.
Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatol. 2016;152(6):645–54.CrossRef
5.
Joly P, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–13.CrossRef
6.
Santoro FA, Stoopler ET, Werth VP. Pemphigus. Dent Clin North Am. 2013;57(4):597–610.CrossRef
7.
Ghaedi F, et al. Drug-induced pemphigus: a systematic review of 170 patients. Int Immunopharmacol. 2021;92: 107299.CrossRef
8.
Yuan PY, et al. Experience in the diagnosis and treatment of a drug-induced pemphigus. Hua Xi Kou Qiang Yi Xue Za Zhi. 2021;39(6):724–7.
9.
Lee CW, Lim JH, Kang HJ. Pemphigus foliaceus induced by rifampicin. Br J Dermatol. 1984;111(5):619–22.CrossRef
10.
Trotta F, et al. Thiopronine-induced pemphigus vulgaris in rheumatoid arthritis. Scand J Rheumatol. 1984;13(1):93–5.CrossRef
11.
Civatte J. Drug-induced pemphigus diseases. Dermatol Monatsschr. 1989;175(1):1–7.
12.
Hebert V, et al. Large international validation of ABSIS and PDAI pemphigus severity scores. J Invest Dermatol. 2019;139(1):31–7.CrossRef
13.
Murrell DF, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–585 e1.
14.
Elston DM, Stratman EJ, Miller SJ. Skin biopsy: biopsy issues in specific diseases. J Am Acad Dermatol. 2016;74(1):1–16; quiz 17–8.
15.
Baum S, et al. Relationship between pemphigus vulgaris severity and PCR-positive herpes simplex virus. Acta Derm Venereol. 2022.
16.
Marano AL, Cardones AR, Hall RP. Inpatient management of autoimmune blistering diseases: an update, review, and practical guide. Current Dermatology Reports. 2019;8(4):208–18.CrossRef
17.
Chryssomallis F, et al. Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol. 1995;34(6):438–42.CrossRef
18.
Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132(12):1435–9.CrossRef
19.
Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. DICP. 1989;23(12):1019–23.CrossRef
20.
Chiappini B, El Khoury G. Risk of atrial fibrillation with high-dose corticosteroids. Expert Opin Drug Saf. 2006;5(6):811–4.CrossRef
21.
Vasheghani-Farahani A, et al. Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis. J Neurol Sci. 2011;309(1–2):75–8.CrossRef
22.
Wu J, Mackie SL, Pujades-Rodriguez M. Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. BMJ Open Diabetes Res Care. 2020;8(1).
23.
Cholera M, Chainani-Wu N. Management of pemphigus vulgaris. Adv Ther. 2016;33(6):910–58.CrossRef
24.
Hooten J, Hall R 3rd, Cardones A. Updates on the management of autoimmune blistering diseases. Skin Therapy Lett. 2014;19(5):1–6.
25.
Hsu DY, et al. Association of pemphigus and systemic corticosteroid use with comorbid health disorders: a case-control study. Dermatol Online J. 2017;23(12).
26.
Zhao W, et al. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive Therapies. Clin Rev Allergy Immunol. 2021;61(3):351–62.CrossRef
27.
Joly P, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40.CrossRef
28.
Murrell DF, Sprecher E. Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2017;177(5):1143–4.CrossRef
29.
Vinay K, et al. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–8.CrossRef
30.
Eming R, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8.CrossRef
31.
Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148(3):602–3.CrossRef
32.
Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–9.CrossRef
33.
Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79(1):97–103.CrossRef
34.
Albers LN, et al. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074–82.CrossRef
35.
Amber KT, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78(15):1527–48.CrossRef
36.
Lamberts A, et al. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248.CrossRef
37.
Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2015;29(4):777–82.CrossRef
38.
Tavakolpour S, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–8.CrossRef
39.
Kanwar AJ, et al. Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases. Indian J Dermatol Venereol Leprol. 2014;80(5):422–6.CrossRef
40.
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–309.CrossRef
41.
Tsutsumi Y, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7(21):2344–51.CrossRef
42.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244 e3.
43.
Amber KT, et al. The controversy of hepatitis C and rituximab: a multidisciplinary dilemma with implications for patients with pemphigus. Indian J Dermatol Venereol Leprol. 2016;82(2):182–3.CrossRef
44.
Rashid H, et al. The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: daily practice data from a retrospective study. J Am Acad Dermatol. 2020;83(5):1503–5.CrossRef
45.
Kushner CJ, et al. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404–9.CrossRef
46.
Pollmann R, et al. Identification of autoreactive B cell subpopulations in peripheral blood of autoimmune patients with pemphigus vulgaris. Front Immunol. 2019;10:1375.CrossRef
47.
Cho MJ, et al. Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nat Commun. 2014;5:4167.CrossRef
48.
Lolis M, et al. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol. 2011;64(3):484–9.CrossRef
49.
Aoyama Y, et al. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy. Eur J Dermatol. 2011;21(1):58–61.CrossRef
50.
Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol. 2008;144(12):1621–4.CrossRef
51.
Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008;58(5):796–801.CrossRef
52.
Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006;39(7):601–7.CrossRef
53.
Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003;13(4):377–81.
54.
Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol. 2002;105(2):192–8.CrossRef
55.
Aoyama Y, et al. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG. Eur J Dermatol. 2008;18(5):557–60.
56.
Yuan L, Haroz S, Franconeri S. Perceptual proxies for extracting averages in data visualizations. Psychon Bull Rev. 2019;26(2):669–76.CrossRef
57.
Ahmed AR, Kaveri S, Spigelman Z. Long-term remissions in recalcitrant pemphigus vulgaris. N Engl J Med. 2015;373(27):2693–4.CrossRef
58.
Amagai M, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595–603.CrossRef
59.
Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45(5):679–90.CrossRef
60.
Ahmed AR, et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25–31.CrossRef
61.
Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol. 2012;166(3):511–7.CrossRef
62.
Murrell DF, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168–74.CrossRef
63.
Grando SA. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs. Int J Dermatol. 2019;58(1):114–25.CrossRef
64.
Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother. 2007;41(10):1604–10.CrossRef
65.
Marie I, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–21.CrossRef
66.
Ahmed AR, Gurcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2011;25(9):1073–9.CrossRef
67.
Asarch A, Razzaque Ahmed A. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy. Pediatr Dermatol. 2009;26(2):197–202.
68.
Heelan K, et al. Cost and resource use of pemphigus and pemphigoid disorders pre- and post-rituximab. J Cutan Med Surg. 2015;19(3):274–82.CrossRef
69.
Valdebran M, Amber KT. Coverage of intravenous immunoglobulin for autoimmune blistering diseases among US insurers. JAMA Dermatol. 2017;153(11):1189–90.CrossRef
70.
Guillaume JC, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol. 1988;124(11):1659–63.CrossRef
71.
Ruocco V, et al. Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol. 1978;98(2):237–41.CrossRef
72.
Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol. 1979;115(6):728–30.
73.
Euler HH, Loffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Dermatol. 1987;123(9):1205–10.CrossRef
74.
Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22(1):35–40.CrossRef
75.
Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol. 1988;124(11):1702–4.CrossRef
76.
Blaszczyk M, et al. Indications for future studies on the treatment of pemphigus with plasmapheresis. Arch Dermatol. 1989;125(6):843–4.CrossRef
77.
Roujeau JC. Plasmapheresis therapy of pemphigus and bullous pemphigoid. Semin Dermatol. 1988;7(3):195–200.
78.
Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? Arch Dermatol. 1988;124(11):1716–8.CrossRef
79.
Harman KE, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177(5):1170–201.CrossRef
80.
Liu Y, et al. Double-filtration plasmapheresis combined with immunosuppressive treatment for severe pemphigus: 10 years’ experience of a single center in China. J Clin Apher. 2021;36(1):20–7.CrossRef
81.
Sinha AA, Hoffman MB, Janicke EC. Pemphigus vulgaris: approach to treatment. Eur J Dermatol. 2015;25(2):103–13.CrossRef
82.
Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity. 2006;39(7):609–16.CrossRef
83.
Dietze J, et al. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris. Atheroscler Suppl. 2017;30:271–7.CrossRef
84.
Behzad M, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166(4):844–52.CrossRef
85.
Meyersburg D, et al. Immunoadsorption in dermatology. Ther Apher Dial. 2012;16(4):311–20.CrossRef
86.
Kolesnik M, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28(6):771–80.CrossRef
87.
Kasperkiewicz M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154–60.CrossRef
88.
Luftl M, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol. 2003;149(3):598–605.CrossRef
89.
Schmidt E, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol. 2003;148(6):1222–9.CrossRef
90.
Shimanovich I, et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol. 2006;31(6):768–74.CrossRef
91.
Mersmann M, et al. Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Arch Dermatol Res. 2016;308(1):31–8.CrossRef
92.
Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res. 2010;302(4):241–53.CrossRef
93.
Beissert S, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041–8.CrossRef
94.
Orvis AK, et al. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183–99; quiz 200–2.
95.
Hopkins ZH, Wu BC, Nousari CH. Rituximab versus mycophenolate mofetil in pemphigus vulgaris. N Engl J Med. 2021;385(11):1055–6.CrossRef
96.
Werth VP, Joly P, Chen DM. Rituximab versus mycophenolate mofetil in pemphigus vulgaris. Reply N Engl J Med. 2021;385(11):1056.
97.
Meggitt SJ, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165(4):711–34.CrossRef
98.
Kotlyar DS, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847–58 e4; quiz e48–50.
99.
Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol. 1995;79(3):264–6.CrossRef
100.
Friedman J, et al. Low-dose pulsed intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients. Cornea. 2014;33(10):1066–70.CrossRef
101.
Calebotta A, et al. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol. 1999;38(3):217–21.CrossRef
102.
Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol. 1996;37(2):93–5.CrossRef
103.
Ozog DM, et al. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol. 2000;136(9):1133–8.CrossRef
104.
Williams HC, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630–8.CrossRef
105.
Kridin K, et al. From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. J Eur Acad Dermatol Venereol. 2019;33(12):2239–52.CrossRef
106.
Goebeler M, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2021.
107.
Zakrzewicz A, et al. Stabilization of keratinocyte monolayer integrity in the presence of anti-desmoglein-3 antibodies through FcRn blockade with efgartigimod: novel treatment paradigm for pemphigus? Cells. 2022;11(6).
108.
Vinall C, Stevens L, McArdle P. Pemphigus vulgaris: a multidisciplinary approach to management. BMJ Case Rep. 2013;2013.
109.
110.
Tabrizi MN, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2007;21(1):79–84.CrossRef
111.
Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris. Dermatol Ther. 2010;23(3):308–11.CrossRef
112.
Abedini R, et al. Comparison of topical nanocolloidal silver formulation use with eosin 2% solution in management of hard-to-heal ulcers in patients with pemphigus vulgaris. J Wound Care. 2020;29(11):664–8.CrossRef
113.
Soares HPL, Brandao EDS, Tonole R. Primary bandages for people with pemphigus vulgaris lesions: an integrative literature review. Rev Gaucha Enferm. 2020;41: e20190259.CrossRef
114.
Brandao E, Santos I, Lanzillotti R. Reduction of pain in clients with autoimmune bullous dermatoses: evaluation by fuzzy logic. Online Brazilian Journal of Nursing. 2016;15(4):675–82.
115.
Higgins EA, West JA. A novel use of topical ketamine for the treatment of oral pemphigus: a case report. J Palliat Care. 2021;36(3):146–7.CrossRef
116.
Basso FG, et al. Proliferation, migration, and expression of oral-mucosal-healing-related genes by oral fibroblasts receiving low-level laser therapy after inflammatory cytokines challenge. Lasers Surg Med. 2016;48(10):1006–14.CrossRef
117.
Suter VGA, Sjolund S, Bornstein MM. Effect of laser on pain relief and wound healing of recurrent aphthous stomatitis: a systematic review. Lasers Med Sci. 2017;32(4):953–63.CrossRef
118.
Minicucci EM, et al. Low-level laser therapy on the treatment of oral and cutaneous pemphigus vulgaris: case report. Lasers Med Sci. 2012;27(5):1103–6.CrossRef
119.
Yousef M, et al. The effect of low level laser therapy on pemphigus vulgaris lesions: a pilot study. J Lasers Med Sci. 2017;8(4):177–80.CrossRef
120.
Pavlic V, et al. Pemphigus vulgaris and laser therapy: crucial role of dentists. Med Pregl. 2014;67(1–2):38–42.CrossRef
121.
Dal Pra KJ, et al. Oral management of pemphigus vulgaris in the intensive care unit. Spec Care Dentist. 2020;40(3):280–4.CrossRef
122.
Akman A, et al. Periodontal status in patients with pemphigus vulgaris. Oral Dis. 2008;14(7):640–3.CrossRef
123.
Gambino A, et al. Conservative approach in patients with pemphigus gingival vulgaris: a pilot study of five cases. Int J Dent. 2014;2014: 747506.CrossRef
124.
Passaro L, Harbarth S, Landelle C. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review. Antimicrob Resist Infect Control. 2016;5:43.CrossRef
125.
Miletta N, et al. The management of pemphigus vulgaris in a burn intensive care unit: a case report and treatment review. J Burn Care Res. 2014;35(5):e357–63.CrossRef
126.
Pakshir K, et al. Identification and antifungal activity profile of candida species isolated from patients with pemphigus vulgaris with oral lesions. Acta Dermatovenerol Croat. 2019;27(3):137–41.
127.
Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update Arch Dermatol. 1996;132(2):203–12.CrossRef
128.
Huang YH, et al. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. J Invest Dermatol. 2012;132(1):92–7.CrossRef
129.
Rinehart JJ, et al. Effects of corticosteroid therapy on human monocyte function. N Engl J Med. 1975;292(5):236–41.CrossRef
130.
Franchimont D, et al. Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures. Regul Pept. 1998;73(1):59–65.CrossRef
131.
Slade JD, Hepburn B. Prednisone-induced alterations of circulating human lymphocyte subsets. J Lab Clin Med. 1983;101(3):479–87.
132.
Esmaili N, et al. Pemphigus vulgaris and infections: a retrospective study on 155 patients. Autoimmune Dis. 2013;2013: 834295.
133.
Leshem YA, et al. Opportunistic infections in patients with pemphigus. J Am Acad Dermatol. 2014;71(2):284–92.CrossRef
134.
Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001;15(2):423–32, viii.
135.
Migita K, et al. Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS ONE. 2013;8(11): e78699.CrossRef
136.
Leshem YA, et al. Is there a role for opportunistic infection prophylaxis in pemphigus? An expert survey. Am J Clin Dermatol. 2017;18(1):127–32.CrossRef
137.
Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7(2):221–8.CrossRef
138.
Stern A, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;10:CD005590.
139.
Smego RA Jr., Moeller MB, Gallis H.A. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med. 1983;143(4):711–8.
140.
Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis. 1986;8(3):427–30.CrossRef
141.
Kirby BD, et al. Legionnaires’ disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore). 1980;59(3):188–205.CrossRef
142.
Amber KT, et al. Determining the incidence of pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis. JAMA Dermatol. 2017;153(11):1137–41.CrossRef
143.
Faraji H, et al. Evaluating the risk-to-benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: a retrospective study with 494 patients. Dermatol Ther. 2022;35(2): e15257.CrossRef
144.
Patel PM, Jones VA, Amber KT. Disease-dependent risk of Pneumocystis Pneumonia: The case of autoimmune blistering disease. Chest. 2020;158(6):2704–5.CrossRef
145.
Ghembaza A, et al. Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest. 2020;158(6):2323–32.CrossRef
146.
Kumar S, et al. Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris. Br J Dermatol. 2017;177(6):1583–9.CrossRef
147.
Lehman JS, el-Azhary RA, Kaposi varicelliform eruption in patients with autoimmune bullous dermatoses. Int J Dermatol. 2016;55(3):e136–40.
148.
Ruocco E, et al. Viruses and pemphigus: an intriguing never-ending story. Dermatology. 2014;229(4):310–5.CrossRef
149.
Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4(5): e004587.CrossRef
150.
Saag KG, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23.CrossRef
151.
Kneiber D, et al. Gastrointestinal symptoms, gastrointestinal bleeding and the role of diet in patients with autoimmune blistering disease: a survey of the International Pemphigus and Pemphigoid Foundation. J Eur Acad Dermatol Venereol. 2019;33(10):1935–40.CrossRef
152.
Kaplan RP, et al. Esophagitis dissecans superficialis associated with pemphigus vulgaris. J Am Acad Dermatol. 1981;4(6):682–7.CrossRef
153.
Schissel DJ, David-Bajar K. Esophagitis dissecans superficialis associated with pemphigus vulgaris. Cutis. 1999;63(3):157–60.
154.
Chang S, et al. Esophageal involvement of pemphigus vulgaris associated with upper gastrointestinal bleeding. Clin Endosc. 2014;47(5):452–4.CrossRef
155.
Trattner A, et al. Esophageal involvement in pemphigus vulgaris: a clinical, histologic, and immunopathologic study. J Am Acad Dermatol. 1991;24(2 Pt 1):223–6.CrossRef
156.
Amber KT, Grando SA. Gastrointestinal prophylaxis in patients with autoimmune blistering disease treated with corticosteroids: an expert survey. Int J Dermatol. 2018;57(11):e125–6.CrossRef
157.
Jones MG, Tsega S, Cho HJ. Inappropriate prescription of proton pump inhibitors in the setting of steroid use: a teachable moment. JAMA Intern Med. 2016;176(5):594–5.CrossRef
158.
Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101(5):521–34.CrossRef
159.
Mimouni D, et al. Pemphigus, analysis of 155 patients. J Eur Acad Dermatol Venereol. 2010;24(8):947–52.CrossRef
160.
Leshem YA, et al. Venous thromboembolism in patients with pemphigus: a cohort study. J Am Acad Dermatol. 2017;77(2):256–60.CrossRef
161.
Kridin K, et al. The risk of pulmonary embolism in patients with pemphigus: a population-based large-scale longitudinal study. Front Immunol. 2019;10:1559.CrossRef
162.
Shaheen MS, Silverberg JI. Association of inflammatory skin diseases with venous thromboembolism in US adults. Arch Dermatol Res. 2021;313(4):281–9.CrossRef
163.
Alikhan R, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963–8.CrossRef
164.
Atzmony L, et al. Incidence of cytomegalovirus-associated thrombosis and its risk factors: a case-control study. Thromb Res. 2010;126(6):e439–43.CrossRef
165.
Stuijver DJF, et al. Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest. 2013;143(5):1337–42.CrossRef
166.
Kahn SR, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.CrossRef
167.
Chmielnicka M, Wozniacka A, Torzecka JD. The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus. Postepy Dermatol Alergol. 2014;31(5):281–8.CrossRef
168.
Ucmak D, et al. The frequency of osteoporosis in patients with pemphigus vulgaris on treatment. Indian J Dermatol Venereol Leprol. 2013;79(2):211–5.CrossRef
169.
Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol. 2010;146(10):1126–31.CrossRef
170.
Hsu DY, et al. Comorbidities and inpatient mortality for pemphigus in the U.S.A. Br J Dermatol. 2016;174(6):1290–8.
171.
Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112(7):962–70.CrossRef
172.
Wormser D, et al. Cumulative oral corticosteroid use increases risk of glucocorticoid-related adverse events in patients with newly diagnosed pemphigus. J Am Acad Dermatol. 2017;77(2):379–81.CrossRef
173.
Ghodsi SZ, et al. Osteoporosis in patients with Pemphigus Vulgaris before steroid therapy. Acta Med Iran. 2014;52(12):879–83.
174.
Chovatiya R, Silverberg JI. Association of pemphigus and pemphigoid with osteoporosis and pathological fractures. Arch Dermatol Res. 2020;312(4):263–71.CrossRef
175.
Marzano AV, et al. Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study. Orphanet J Rare Dis. 2015;10:8.CrossRef
176.
Amagai M. Pemphigus vulgaris and its active disease mouse model. Curr Dir Autoimmun. 2008;10:167–81.CrossRef
177.
Pacifici R. The immune system and bone. Arch Biochem Biophys. 2010;503(1):41–53.CrossRef
178.
El-Komy MH, Samir N, Shaker OG. Estimation of vitamin D levels in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2014;28(7):859–63.CrossRef
179.
Joshi N, et al. Vitamin D deficiency and lower TGF-beta/IL-17 ratio in a North Indian cohort of pemphigus vulgaris. BMC Res Notes. 2014;7:536.CrossRef
180.
Moravvej H, Mozafari N, Younespour S. Serum 25-hydroxy vitamin D level in patients with pemphigus and its association with disease severity. Clin Exp Dermatol. 2016;41(2):142–7.CrossRef
181.
Zarei M, et al. Evaluation of vitamin D status in newly diagnosed pemphigus vulgaris patients. Iran J Public Health. 2014;43(11):1544–9.
182.
Amber KT, Grando SA. Current practices for the prophylaxis against bone mineral density loss in patients with autoimmune blistering disease treated with corticosteroids: an expert survey. J Eur Acad Dermatol Venereol. 2018;32(11):e416–8.CrossRef
183.
Overman RA, et al. United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2014;66(11):1644–52.CrossRef
184.
Buckley L, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2017;69(8):1095–110.CrossRef
185.
Tee SI, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2012;148(3):307–14.CrossRef
186.
Furukawa F, et al. Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy. Clin Exp Dermatol. 2011;36(2):165–8.CrossRef
187.
Yaghubi E, et al. Effects of l-carnitine supplementation on cardiovascular and bone turnover markers in patients with pemphigus vulgaris under corticosteroids treatment: a randomized, double-blind, controlled trial. Dermatol Ther. 2019;32(5): e13049.CrossRef
188.
van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87.CrossRef
Metadata
Title
Pemphigus for the Inpatient Dermatologist
Authors
Connor Cole
Kyle Amber
Publication date
02-09-2022
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 4/2022
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-022-00369-2

Other articles of this Issue 4/2022

Current Dermatology Reports 4/2022 Go to the issue

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Strategies for Effective Management of Hidradenitis Suppurativa in the Hospital Setting

Covid-19 in Dermatology (J. M. Gelfand, Section editor)

Impact of the COVID-19 Pandemic on the Delivery of Dermatological Care

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Off-Label Uses of Rituximab in Dermatology

Teledermatology (D Oh, Section Editor)

Teledermatology in Rural, Underserved, and Isolated Environments: A Review

HOT TOPIC

Epidemiology of Hidradenitis Suppurativa: Current Status

Covid-19 in Dermatology (J. M. Gelfand, Section editor)

The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review